A recentpublication has demonstrated the feasibility of molecular imagingtargeting MSLN using a nanobody alternative protein scaffold in thecontext of ovarian cancer cell lines. Our current report broadens the scope of candidate molecular imagingagents targeting MSLN, with a focus on PM, including the applicationfor radioligand therapy. This evidence concerns the gene MSLN and ovarian carcinoma.